Background: Breast carcinoma is the most common malignant tumour and leading cause of cancer death among women worldwide. VEGF being a powerful mediator of angiogenesis, plays a major role in local growth as well as metastasis of many solid tumours including breast carcinoma. Objective: This study aimed to evaluate the significance of VEGF expression in breast cancer and its correlation with prognostic parameters. Materials and methods: This study was conducted over a period of one year
Introduction:
Breast cancer is the second most common cancer in the world and by far the most frequent cancer among women with an estimated 1.67 million new cancer cases diagnosed in 2012, according to globocan (WHO). Highest number of deaths due to breast carcinoma (70218 women in the year2012) was reported from India 1 . Angiogenesis has been shown to be a critical aspect of tumour growth and metastasis [2] [3] [4] . The induction of angiogenesis by a tumour is a controlled process, influenced by angiogenic and angiostatic factors which involve a complex interaction between tumour and endothelial cells [4] [5] [6] . Among the many reported angiogenic factors, vascular endothelial growth factor (VEGF) is the most powerful endothelial cell specific mitogen that plays a key role in the complicated process of angiogenesis. VEGF also known as vascular permeability factor, is a glycoprotein of 32-42 kDa. The VEGF family currently includes six known members: VEGF-A (commonly known as VEGF), VEGF-B, VEGF-C, VEGF-D, VEGF-E and placental growth factor [7] [8] [9] . VEGF activates tyrosine kinase receptors, VEGFR-1 (also referred to as FLT1) and VEGFR-2 (or KDR) located in the endothelium, which leads to stimulation of endothelial migration, proliferation, permeability, .Recent evidence suggests that VEGF not only plays a role in inducing angiogenesis but also is promotes the survival of new vessels formed with in the tumour 11 . A large number of studies conducted all over the world demonstrated that VEGF could be used as an indicator of significant poor outcome in patients of breast carcinoma. [12] [13] [14] . Therefore the current study tries to find the expression of VEGF and its correlation with other prognostic parameters of breast carcinoma as a possible explanation for the aggressive behaviour of this tumour. 
Discussion:
Causation of breast carcinoma is multifactorial and angiogenesis has a pivotal role 15 . The biology of breast carcinoma remains poorly understood as the knowledge about individual prognostic factors provides limited information 16 . Inspite of a huge number of studies role of anti VEGF therapy is still debatable in case of breast cancer 17 .
In our study VEGF was expressed in 91.2 % of breast carcinoma which was concordant with other previous studies by Vogl G et al (98% VEGF positivity) 20 , Anca Maria Cîmpean et al (87.15%) 21 and Adams J et al (80%) 18 . Whereas studies by Rivkin SE et al. showed very low expression (37%) 19 . Presence of significant positive correlation between grade of breast carcinoma (chart: 1) and VEGF expression has been also shown by other researchers in different studies which explain the role of VEGF gene in tumour angiogenesis and tumour progression 18, 20, 22, 25 . From chart no: 3, it has been clearly shown that Tstage of breast carcinoma (tumour size) is positively correlated with VEGF expression (p value : <0.005) and other investigators also found similar result 20, 25 . Adams J et al 18 and Granato AM et al 22 has reported that there is a significant negative correlation between VEGF and ER expression (chart no: 2) which is similar with our study findings (rho: -0.470, p-.002). Though many of the researchers 20, 23 have failed to show any association between angiogenesis and HER2, we have noticed an association of HER2 and angiogenesis like Blackwell KL et al 24 and a significant correlation with histological type like Cimpean A M et al 21 .
Conclusion:
From the observations of our study it can be concluded that VEGF has the potential to be considered as an important prognostic parameter in breast carcinoma. Targeted therapy against it may be beneficial for the patients specially, who are triple negative and have no specific treatment other than chemotherapy. As it was a time bound study of relatively small numbers of cases with limited scope of follow up, a wider evaluation involving large no of cases provided with proper follow up facility is recommended to validate its therapeutic efficacy. 
